Full Text View
Tabular View
No Study Results Posted
Related Studies
8-Chloro-Adenosine in Chronic Lymphocytic Leukemia
This study is currently recruiting participants.
Verified by M.D. Anderson Cancer Center, December 2009
First Received: July 10, 2008   Last Updated: December 23, 2009   History of Changes
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
FDA Office of Orphan Products Development
Information provided by: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00714103
  Purpose

The goal of this clinical research study is to find the highest safe dose of the drug 8-chloro-adenosine that can be given in the treatment of chronic lymphocytic leukemia (CLL). Another goal is to learn how effective the drug is at treating leukemia.


Condition Intervention Phase
Leukemia
Chronic Lymphocytic Leukemia
Drug: 8-Chloro-Adenosine
Phase I

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase I Study OF 8-Chloro-Adenosine in Previously Treated Patients With Chronic Lymphocytic Leukemia.

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Dose-limiting Toxicity and Maximum Tolerated Dose [ Time Frame: During first course of treatment blood tests on Days 3 and 5; then weekly (± 3 days) evaluations and routine blood tests. Toxicity evaluation completed four weeks following initial 8-Chloro-adenosine administration. ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 28
Study Start Date: June 2008
Estimated Study Completion Date: August 2011
Estimated Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
8-Chloro-Adenosine: Experimental Drug: 8-Chloro-Adenosine
45 mg/m^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).

Detailed Description:

8-Chloro-adenosine is a new drug similar to other drugs already approved by the FDA for the treatment of CLL and other types of cancer. 8-Chloro-adenosine belongs to a class of chemotherapy drugs called purine analogues that work to treat cancer by their ability to interfere with cancer cell metabolism, causing cell death.

Before you can start treatment on the study, you will have what are called "screening tests". These tests will help the doctor decide if you are eligible to take part in the study. You will have a complete medical history and physical exam. Routine blood tests (about 1 tablespoon) will be performed. Your treating doctor may order other tests if he/she thinks they are necessary. Women who are able to have children must have a negative blood pregnancy test.

If you are eligible, you will receive 8-chloro-adenosine as an infusion into a vein once a day for five days in a row. Each infusion will take about 1 hour. This 5-day treatment will be repeated every 4 weeks (± 3 days) (1 course).

This is a dose escalation study. Patients treated on this study will be treated in groups of 3. The first group will receive the lowest dose of the drug. If the type, number, and severity of any side effects experienced are acceptable, the next group of 3 patients will receive the next higher dose of drug. The dose of drug will be increased for each new group until the highest safe dose is found.

For your first course only, you will have blood tests (about 1 tablespoon) on Day 3 and Day 5 of treatment to monitor for safety. After that, you will have weekly (± 3 days) evaluations and routine blood tests (about 1 tablespoon) in the clinic at UTMDACC. During these evaluations, you will also have a physical exam and be asked about any side effects you may have experienced. You will be evaluated for improvement in your CLL. If your disease is stable or responding to treatment, you may continue with treatment. If your disease improves to the point that your doctor feels that you are in complete remission, he or she will request you to have a bone marrow biopsy to confirm complete remission.

If your disease is worsening and it appears that the treatment is not helping you, then you will stop treatment with 8-chloro-adenosine and may begin other treatment at the direction of your treating doctor. If you have unacceptable side effects, you may be taken off treatment.

If you stop treatment, you will be evaluated in the clinic and have routine blood tests (about 1 tablespoon) once a week for the first month, twice a month for the next 2 months, then once a month from then on. During these evaluations, you will have a physical exam and be asked about any side effects you may have experienced. If you begin other treatment, your scheduled follow-up will end.

This is an investigational study. 8-Chloro-adenosine is not approved by the FDA and is not commercially available. A total of up to 28 patients will take part in this study. All will be enrolled and treated at M. D. Anderson.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have a diagnosis of chronic lymphocytic leukemia and must be previously treated with more than one treatment regimen, including a purine-analogue based treatment.
  • Patients must be Rai Stage III or IV OR Rai Stage 0-II and have one or more criteria for active disease as defined by the NCI-Working Group as: a) weight loss of more than 10% in the last 6 months; b) fatigue; c) fever or night sweats without evidence of infection; d) progressive anemia or thrombocytopenia; e) progressive lymphocytosis with a lymphocyte doubling time </= 6 months; or f) marked hypogammaglobulinemia or paraproteinemia.
  • All patients must have a Zubrod performance status of </= 2.
  • All patients must be age >/= 18 years.
  • Patients may not receive concurrent treatment for their CLL and must have been off treatment (chemotherapy, immunotherapy, or radiotherapy) for 4 weeks prior to treatment on this study and recovered from toxic effects of that therapy.
  • All patients must have adequate renal function indicated by serum creatinine </=2.5x upper limits of normal (ULN) and adequate liver function indicated by ALT or AST </= 2.5x ULN AND total bilirubin </= 2.5x ULN.
  • All patients must have a pre-treatment platelet count of >/= 50,000 /µl and not require transfusion to maintain this platelet count.
  • All patients or appropriate surrogate must provide informed consent.

Exclusion Criteria:

  • Patients with active uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia purpura.
  • Patients with active uncontrolled fungal, bacterial, or viral infection.
  • Patients who are pregnant or breast-feeding.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00714103

Contacts
Contact: William G. Wierda, M.D. 713/745-0428 wwierda@mdanderson.org

Locations
United States, Texas
The University of Texas M.D. Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: William G. Wierda, M.D.     713-745-0428     wwierda@mdanderson.org    
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: William G. Wierda, M.D. M.D. Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: The University of Texas M.D. Anderson Cancer Center ( William G. Wierda, M.D./Associate Professor )
Study ID Numbers: 2004-0144, 3550
Study First Received: July 10, 2008
Last Updated: December 23, 2009
ClinicalTrials.gov Identifier: NCT00714103     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:
Leukemia
Chronic Lymphocytic Leukemia
CLL
8-Chloro-Adenosine
purine analogues
Cancer

Additional relevant MeSH terms:
Vasodilator Agents
Leukemia, Lymphoid
Neoplasms by Histologic Type
Immunoproliferative Disorders
Immune System Diseases
Physiological Effects of Drugs
Cardiovascular Agents
Pharmacologic Actions
Leukemia
Lymphatic Diseases
Neoplasms
Leukemia, Lymphocytic, Chronic, B-Cell
Sensory System Agents
Therapeutic Uses
Anti-Arrhythmia Agents
Peripheral Nervous System Agents
Analgesics
Leukemia, B-Cell
Lymphoproliferative Disorders
Central Nervous System Agents
Adenosine

ClinicalTrials.gov processed this record on February 08, 2010